User login
Key clinical point: A chemotherapy-free combination of pyrotinib, letrozole, and dalpiciclib demonstrated promising antitumor activity and an acceptable safety profile in the neoadjuvant setting in patients with triple-positive breast cancer (TPBC).
Major finding: After 5 cycles of the 4-week treatment, a substantial proportion (30.4%) of patients achieved pathological complete response in both the breast and lymph nodes. The most common adverse events were neutropenia (93%), leukopenia (90%), diarrhea (86%), anemia (68%), and oral mucositis (63%).
Study details: Findings are from the phase 2, MUKDEN 01 trial including 81 patients with stage II-III TPBC who were assigned to receive neoadjuvant treatment with pyrotinib+letrozole+dalpiciclib.
Disclosures: This study did not report a source of funding. The authors declared no conflicts of interest.
Source: Niu N et al. A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancer. Nat Commun. 2022;13:7043 (Nov 17). Doi: 10.1038/s41467-022-34838-w
Key clinical point: A chemotherapy-free combination of pyrotinib, letrozole, and dalpiciclib demonstrated promising antitumor activity and an acceptable safety profile in the neoadjuvant setting in patients with triple-positive breast cancer (TPBC).
Major finding: After 5 cycles of the 4-week treatment, a substantial proportion (30.4%) of patients achieved pathological complete response in both the breast and lymph nodes. The most common adverse events were neutropenia (93%), leukopenia (90%), diarrhea (86%), anemia (68%), and oral mucositis (63%).
Study details: Findings are from the phase 2, MUKDEN 01 trial including 81 patients with stage II-III TPBC who were assigned to receive neoadjuvant treatment with pyrotinib+letrozole+dalpiciclib.
Disclosures: This study did not report a source of funding. The authors declared no conflicts of interest.
Source: Niu N et al. A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancer. Nat Commun. 2022;13:7043 (Nov 17). Doi: 10.1038/s41467-022-34838-w
Key clinical point: A chemotherapy-free combination of pyrotinib, letrozole, and dalpiciclib demonstrated promising antitumor activity and an acceptable safety profile in the neoadjuvant setting in patients with triple-positive breast cancer (TPBC).
Major finding: After 5 cycles of the 4-week treatment, a substantial proportion (30.4%) of patients achieved pathological complete response in both the breast and lymph nodes. The most common adverse events were neutropenia (93%), leukopenia (90%), diarrhea (86%), anemia (68%), and oral mucositis (63%).
Study details: Findings are from the phase 2, MUKDEN 01 trial including 81 patients with stage II-III TPBC who were assigned to receive neoadjuvant treatment with pyrotinib+letrozole+dalpiciclib.
Disclosures: This study did not report a source of funding. The authors declared no conflicts of interest.
Source: Niu N et al. A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancer. Nat Commun. 2022;13:7043 (Nov 17). Doi: 10.1038/s41467-022-34838-w